Navigation Links
Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
Date:11/9/2008

is a recombinant adeno-associated viral (rAAV) vector that transfers the SERCA2a gene into heart muscle cells. MYDICAR is delivered in a single dose directly to the heart muscle during a short outpatient procedure, performed in a standard cardiac catheterization laboratory via a small incision in the upper leg.

"These data demonstrate the safety of MYDICAR, and the improvements in cardiac function and overall condition observed in some patients further validate our target and approach," said Krisztina M. Zsebo, Ph.D., Chief Executive Officer of Celladon. "Given these early encouraging results, we are excited to have been given clearance to move into phase 2 of our study to continue to evaluate the ability of MYDICAR to improve heart function in more patients."

CUPID, which is funded by Celladon, is a Phase 1/2 trial. The Phase 1 portion reported today is an open-label, sequential dose escalation study. The Phase 2 portion is a randomized, double-blind, placebo-controlled, parallel-group, dose ranging trial that compares the use of MYDICAR at two or three dose levels with placebo. CUPID is expected to enroll 46 patients with advanced heart failure at 15 U.S. medical centers.

Study Results

Data from the Phase I in advanced heart failure was presented, and demonstrated that MYDICAR had an acceptable safety profile in these first nine patients, as determined by study investigators and an independent safety committee. In addition, improvements from baseline to six months across a number of parameters important in assessing heart failure status were observed, including symptomatic (5 patients), functional (4 patients), biomarker (2 patients) and left ventricular function/remodeling (6 patients). Of the nine patients treated, two with low levels of pre-existing antibodies to the AAV vector did not show improvement in these parameters.

The data are consistent with safety established for other rAAV vectors, which has been demonstrated in cl
'/>"/>

SOURCE Celladon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
5. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
6. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
10. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
11. Lutonix Inc. Announces $20 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... BOCA RATON, Fla. , Nov. 24, 2014  Marta ... Aesthetic Medicine, Boca Raton , FL and international ... dermatologic physicians selected from the United States ... 14-16 in Istanbul, Turkey . Here, at ... truly meet West, as world renowned facial plastic surgery experts ...
(Date:11/24/2014)... Theater, LLC, announced today that their technology will be ... Europe,s first simulation center, The ... Planner (SRP) and the Surgical Navigation Advanced Platform (SNAP) ... navigation and augmented reality capabilities in the operating room ... Department of Neurosurgery at Mount Sinai Health System in ...
(Date:11/24/2014)... 2014  Pifflers United Chronic and Invisible Illnesses ... of results of a study of ActiPatch®, a ... of fibromyalgia pain. The results demonstrated that when ... significant clinically meaningful pain reduction can be achieved. ... fibromyalgia used ActiPatch® for 7 days and were ...
Breaking Medicine Technology:Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3
... , , , , WOONSOCKET, R.I., Jan. 8 ... (NYSE: CVS ) and the pioneer and largest ... become the first retail clinic to be re-accredited and earn ... periods by having demonstrated compliance with The Joint Commission,s national ...
... SOUTH SAN FRANCISCO, Dec. 31 Anesiva, Inc. (Nasdaq: ... the closing conditions set forth in the Agreement and Plan ... Corporation, a wholly-owned subsidiary of Anesiva, Arcion Therapeutics, Inc. ("Arcion") ... the agreement, each of the Arcion stockholders listed on Schedule ...
Cached Medicine Technology:CVS Caremark's MinuteClinic Becomes First Retail Clinic Provider to Achieve Consecutive Accreditation Awards From The Joint Commission 2CVS Caremark's MinuteClinic Becomes First Retail Clinic Provider to Achieve Consecutive Accreditation Awards From The Joint Commission 3CVS Caremark's MinuteClinic Becomes First Retail Clinic Provider to Achieve Consecutive Accreditation Awards From The Joint Commission 4Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed 2
(Date:11/26/2014)... November 26, 2014 For its ... published The AIS Report on Blue Cross and Blue ... Inc. on the varied strategies the two Blues plans ... compliance with treatments for sleep apnea, ranging from brick-and-mortar ... because it’s linked to increased rates of a variety ...
(Date:11/26/2014)... 2014 GI for Life announced today, ... in prices of their popular nutritional supplements: ColoVite ... . Discounts of 40% will be offered for ... Life’s proprietary ColoVite supplement is a scientifically formulated vitamin ... health. One easy-to-take colon vitamin with ALL the nutrients ...
(Date:11/26/2014)... 2014 Anthropologists have identified concrete ... and stopping Ebola, improve international support, and pave ... in West Africa. , The report, “Strengthening ... Anthropologists Offer Insights,” will be made public during ... Association (AAA), Fri., Dec. 5, 11 a.m., at ...
(Date:11/26/2014)... For those with a New Year’s resolution ... BODYPUMP™ classes at the University of Colorado Anschutz Health ... looking for. The 45- 60 minute classes have just started ... Center fitness club memberships. , LES MILLS BODYPUMP™ exercise classes ... are aimed at fast results , By focusing on ...
(Date:11/26/2014)... of the most important and vital decisions a woman ... choosing the ideal wedding dress and bridesmaid dresses. BellasDress.com ... quality outfits. Today, BellasDress.com has unveiled its new range ... suitable bridesmaid gowns here at discount prices. , Formal ... and highlight all their most beautiful features while drawing ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Royal Blue Bridesmaid Dresses Now Are Available for Christmas at BellasDress.com 2
... YORK, April 15 An internationally-known brand name,New York ... Bruce,of Wellness" by Shape magazine, Susan Powter,s "Stop the ... personal story of losing over,l30 pounds as a single ... and fitness industry forever. Now, recently returned to public,life ...
... YARDLEY, Pa., April 15 Breakaway Technologies, Inc.,(BTI), ... that 2008 marks its 10th anniversary. BTI has ... 10 years., "Breakaway was founded to provide ... problems, whether they needed a technology or a,business ...
... diuretics more than double risk for fractures, study finds ... drugs commonly prescribed to treat heart failure and hypertension, ... men, says a U.S. study. , Researchers evaluated 3,269 ... examination between 2000 and 2002, with a follow-up visit ...
... and CAMARILLO, Calif., April 15 IBM (NYSE:,IBM) ... today announced GSMS will be ready to comply ... GSMS is using,IBM technology to manage serialized drug ... The California Board of Pharmacy recently gave ...
... Adults with Autism and Other ... ... annual,in-store fundraising and awareness campaign to bring new hope and,opportunities to ... of dollars to fund Easter Seals, autism and,disability services, provide job ...
... 15, 2008 -- Results of a phase IV, open ... subcutaneous Rebif (interferon beta-1a) provide clinical evidence that the ... months of continued therapy in patients with relapsing-remitting multiple ... April 2008 issue of the Current Medical Research and ...
Cached Medicine News:Health News:Susan Powter The Politics of Stupid: The Cure for Obesity 2Health News:Breakaway Technologies Celebrates 10 Years in Business 2Health News:Heart Failure Drugs Linked to Hip Bone Loss in Older Men 2Health News:Golden State Medical Supply Selects IBM Technology to Comply With California Prescription Drug Pedigree Regulations 2Health News:Golden State Medical Supply Selects IBM Technology to Comply With California Prescription Drug Pedigree Regulations 3Health News:Safeway's In-Store Disabilities Campaign to Benefit Easter Seals 2Health News:Study shows that high-dose, high-frequency interferon produces no additional benefit 2
... eyewear designs with children in mind, making ... and stay-put cable temples. Its not surprising ... Research as the best selling childrens collection ... so popular is its ability to keep ...
Inquire...
... new GUCCI DONNA eyewear collection celebrates the ... a vintage yet contemporary feel, the unmistakable ... new GUCCI UOMO optical and sunglass collection, ... classic lines with cutting-edge design that is ...
Inquire...
Medicine Products: